老年高血压合并衰弱的药物治疗现状

Current status of pharmacotherapy for elderly hypertension complicated with frailty

摘要

在老年人群中，高血压和衰弱都有很高的流行率，两者常同时存在并相互影响，对老年人的健康和生活质量构成共同威胁。目前的主流医学共识认为，在启动老年高血压患者的降压治疗前，必须进行衰弱评估。然而，针对老年高血压合并衰弱的药物治疗，目前尚无标准化的方案，其核心原则是治疗目标的个体化和用药策略的个性化。各类降压药对衰弱的影响尚存争议，而其他类别药物的疗效与安全性也仍在研究中。中医药治疗或可成为破解该领域治疗瓶颈的突破口。

Abstract

Hypertension and frailty are both highly prevalent conditions in the elderly population. They often coexist and mutually exacerbate each other, posing a joint threat to the health and quality of life of older adults. Current mainstream medical consensus holds that frailty assessment must be conducted before initiating antihypertensive therapy in elderly hypertensive patients. However, there is no standardized protocol for the pharmacotherapy of hypertension combined with frailty in the elderly. The core principles are individualized treatment goals and personalized medication strategies. The impact of various antihypertensive drugs on frailty remains controversial, and the efficacy and safety of other drug classes are still under investigation. Traditional chinese medicine treatment may serve as a breakthrough to address the therapeutic bottlenecks in this field.

关键词

老年 / 高血压 / 衰弱 / 药物治疗

Key words

elderly / hypertension / frailty / pharmacotherapy

参考文献

[1] 张梅, 吴静, 张笑, 等 . 2018年中国成年居民高血压患病与控制状况研究[J]. 中华流行病学杂志， 2021， 42(10): 1780-1789.

[2] Clegg A, Young J, Iliffe S, et al. Frailty in elderly people[J]. Lancet， 2013， 381(9868): 752-762.

[3] He B, Ma Y, Wang C, et al. Prevalence and risk factors for frailty among community—dwelling older people in China: a systematic review and meta—analysis[J]. J Nutr Health Aging， 2019， 23(5): 442-450.

[4] 中华医学会心血管病学分会老年学组, 国家老年疾病临床医学研究中心 (解放军总医院) . 老年心血管疾病合并衰弱评估与管理中国专家共识[J]. 中华老年多器官疾病杂志， 2023， 22(7): 481-491.

[5] Panza F, Lozupone M, Solfrizzi V, et al. Different cognitive frailty models and health— and cognitive—related outcomes in older age: from epidemiology to prevention[J]. J Alzheimers Dis， 2018， 62(3): 993-1012.

[6] Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action[J]. J Am Med Dir Assoc， 2013， 14(6): 392-397.

[7] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci， 2001， 56(3): M146-156.

[8] Buta BJ, Walston JD, Godino JG, et al. Frailty assessment instruments: systematic characterization of the uses and contexts of highly—cited instruments[J]. Ageing Res Rev， 2016， 26： 53-61.

[9] 中国老年医学学会高血压分会, 北京高血压防治协会, 国家老年疾病临床医学研究中心, 等 . 中国老年高血压管理指南2023[J]. 中华高血压杂志， 2023， 31(6): 508-538.

[10] Ye B, Li Y, Wang Y, et al. A Modified frailty phenotype used for identifying frailty in health care practice: validation among Chinese older adults[J]. J Am Med Dir Assoc， 2024， 25(7): 105016.

[11] 中华医学会老年医学分会 . 老年患者衰弱评估与干预中国专家共识[J]. 中华老年医学杂志， 2017， 36(3): 251-256.

[12] 程青霞, 张丽萍, 郭蕾 . 老年高血压患者衰弱患病率的meta分析[J]. 现代医药卫生， 2023， 39(8): 1336-1343.

[13] 赵璨, 刘姗姗, 李净兵, 等 . 探析老年原发性高血压病人衰弱综合征发生率及相关危险因素[J]. 实用老年医学， 2023， 37(2): 147-150.

[14] 陈雨萍, 张先庚, 曹俊, 等 . 社区老年高血压患者衰弱现状及影响因素[J]. 中国老年学杂志， 2022， 42(2): 459-462.

[15] 骆沁, 姚可茹, 唐玺, 等 . 老年高血压患者衰弱患病情况及危险因素分析[J]. 湘南学院学报 (医学版)， 2023， 25(1): 52-56.

[16] Song X, Zhang W, Hallensleben C, et al. Associations between obesity and multidimensional frailty in older Chinese people with hypertension[J]. Clin Interv Aging， 2020， 15： 811-820.

[17] 郑淑娟, 李瑜, 欧阳菊艳, 等 . 老年高血压合并衰弱住院患者的营养状况调查及相关因素分析[J]. 中华老年心脑血管病杂志， 2024， 26(8): 886-891.

[18] Teng L, Wang D, Zhou Z, et al. Associations among frailty status, hypertension, and fall risk in community—dwelling older adults[J]. Int J Nurs Sci， 2024， 11(1): 11-17.

[19] Li L, Duan L, Wang B, et al. Association of changes in frailty with mortality in the aged with hypertension[J]. Sci Rep， 2025， 15(1): 12422.

[20] Ravindrarajah R, Hazra NC, Hamada S, et al. Systolic blood pressure trajectory, frailty, and all—cause mortality ＞80 years of age: cohort study using electronic health records[J]. Circulation， 2017， 135(24): 2357-2368.

[21] Ma L, Zhang L, Sun F, et al. Frailty in Chinese older adults with hypertension: prevalence, associated factors, and prediction for long—term mortality[J]. J Clin Hypertens (Greenwich)， 2018， 20(11): 1595-1602.

[22] Shrauner W, Lord EM, Nguyen XT, et al. Frailty and cardiovascular mortality in more than 3 million US Veterans[J]. Eur Heart J， 2022， 43(8): 818-826.

[23] Hu K, Zhou Q, Jiang Y, et al. Association between frailty and mortality, falls, and hospitalization among patients with hypertension: a systematic review and meta—analysis[J]. Biomed Res Int， 2021， 2021： 2690296.

[24] Warwick J, Falaschetti E, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the hypertension in the very elderly trial (HYVET) study, a double—blind, placebo—controlled study of antihypertensives in people with hypertension aged 80 and over[J]. BMC Med， 2015， 13： 78.

[25] Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial [J]. JAMA， 2016， 315(24): 2673-2682.

[26] Kremer KM, Braisch U, Rothenbacher D, et al. Systolic blood pressure and mortality in community—dwelling older adults: frailty as an effect modifier[J]. Hypertension， 2022， 79(1): 24-32.

[27] Falk JM, Froentjes L, Kirkwood JE, et al. Higher blood pressure targets for hypertension in older adults[J]. Cochrane Database Syst Rev， 2024， 12(12): CD011575.

[28] Vetrano DL, Palmer KM, Galluzzo L, et al. Hypertension and frailty: a systematic review and meta—analysis[J]. BMJ Open， 2018， 8(12): e24406.

[29] 中国老年医学学会高血压分会, 国家老年疾病临床医学研究中心中国老年心血管病防治联盟 . 中国老年高血压管理指南2019[J]. 中国心血管杂志， 2019， 24（ 1）： 1-23.

[30] McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension[J]. Eur Heart J， 2024， 45(38): 3912-4018.

[31] Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Hypertension， 2025， 82(10): e212-e316.

[32] 郭艺芳, 杨宁 . 强化血压控制中国专家建议[J]. 中华高血压杂志， 2022， 30(2): 113-117.

[33] 朱平 . 老年人高血压的特点及诊疗进展[J]. 中华老年心脑血管病杂志， 2021， 23(8): 785-787.

[34] Aguirre F, Abrigo J, Gonzalez F, et al. Protective effect of angiotensin 1—7 on sarcopenia induced by chronic liver disease in mice[J]. Int J Mol Sci, 2020, 21(11): 3891.

[35] Veronese N, Stubbs B, Smith L, et al. Angiotensin—converting enzyme inhibitor use and incident frailty: a longitudinal cohort study[J]. Drugs Aging， 2019， 36(4): 387-393.

[36] Achison M, Adamson S, Akpan A, et al. Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial[J]. J Cachexia Sarcopenia Muscle， 2022， 13(2): 858-871.

[37] Chuang SY, Pan WH, Chang HY, et al. Protective effect of calcium channel blockers against frailty in older adults with hypertension[J]. J Am Geriatr Soc， 2016， 64(6): 1356-1358.

[38] Lopes De Oliveira T, Tang B, Bai G, et al. Effects from medications on functional biomarkers of aging in three longitudinal studies of aging in Sweden[J]. Aging Cell， 2024， 23(6): e14132.

[39] Ke Z, Wen H, Huang R, et al. Long—term insulin resistance is associated with frailty, frailty progression, and cardiovascular disease[J]. J Cachexia Sarcopenia Muscle， 2024， 15(4): 1578-1586.

[40] Santulli G, Visco V, Varzideh F, et al. Prediabetes increases the risk of frailty in prefrail older adults with hypertension: beneficial effects of metformin[J]. Hypertension， 2024， 81(7): 1637-1643.

[41] Rennie KJ, Witham M, Bradley P, et al. MET—PREVENT: metformin to improve physical performance in older people with sarcopenia and physical prefrailty/frailty — protocol for a double—blind, randomised controlled proof—of—concept trial[J]. BMJ Open， 2022， 12(7): e061823.

[42] Chen C, Kassan A, Castañeda D, et al. Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway[J]. Hypertens Res， 2019， 42(7): 960-969.

[43] Wimmer MI, Bartolomaeus H, Anandakumar H, et al. Metformin modulates microbiota and improves blood pressure and cardiac remodeling in a rat model of hypertension[J]. Acta Physiol (Oxf)， 2024， 240(11): e14226.

[44] Oliveira P, de Sousa GJ, Birocale AM, et al. Chronic metformin reduces systemic and local inflammatory proteins and improves hypertension—related cardiac autonomic dysfunction[J]. Nutr Metab Cardiovasc Dis， 2020， 30(2): 274-281.

[45] Zhou L, Liu H, Wen X, et al. Effects of metformin on blood pressure in nondiabetic patients: a meta—analysis of randomized controlled trials[J]. J Hypertens， 2017， 35(1): 18-26.

[46] Mone P, Martinelli G, Lucariello A, et al. Extended—release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS study[J]. Cardiovasc Diabetol， 2023， 22(1): 94.

[47] Gupta R, Maitz T, Egeler D, et al. SGLT2 inhibitors in hypertension: role beyond diabetes and heart failure[J]. Trends Cardiovasc Med， 2023， 33(8): 479-486.

[48] Santulli G, Varzideh F, Forzano I, et al. Functional and clinical importance of SGLT2—inhibitors in frailty: from the kidney to the heart[J]. Hypertension， 2023， 80(9): 1800-1809.

[49] Huang BB, Zhang YJ, Ruan GF, et al. The Impact of SGLT1 inhibition on frailty and sarcopenia: a mediation Mendelian randomization study[J]. J Cachexia Sarcopenia Muscle， 2024， 15(6): 2693-2704.

[50] van Dronkelaar C, van Velzen A, Abdelrazek M, et al. Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: a systematic review[J]. J Am Med Dir Assoc， 2018， 19(1): 6-11.

[51] Yu X, Chen X, Wu W, et al. Zinc alleviates diabetic muscle atrophy via modulation of the SIRT1/FoxO1 autophagy pathway through GPR39[J]. J Cachexia Sarcopenia Muscle， 2025， 16(2): e13771.

[52] Guaraldi G, Erlandson KM, Milic J, et al. Can statin preventative treatment inform geroscience—guided therapeutics?[J]. Aging Cell， 2023， 22(12): e13998.

[53] Alturki M, Liberman K, Delaere A, et al. Effect of antihypertensive and statin medication use on muscle performance in community—dwelling older adults performing strength training[J]. Drugs Aging， 2021， 38(3): 253-263.

[54] Adhikari A, Tripathy S, Chuzi S, et al. Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies[J]. J Clin Lipidol， 2021， 15(1): 22-32.

[55] Mondal A, Li A, Edusa S, et al. Does statin use in frail patients provide survival benefits? Insights from a meta—analysis[J]. Curr Probl Cardiol, 2024, 49(1 Pt A): 102038.

[56] 李琪, 李丽丽, 芮小勇, 等 . 不同剂量阿托伐他汀钙对中重度衰弱高龄患者肌少症的影响[J]. 中华老年多器官疾病杂志， 2019， 18(4): 247-251.

[57] Taylor BA, Thompson PD . Statin—associated muscle disease: advances in diagnosis and management[J]. Neurotherapeutics， 2018， 15(4): 1006-1017.

[58] Chu Z, Yue W, Mu Q, et al. Effects of statin use on blood pressure and other hypertension—related outcome indicators in hypertensive patients: a systematic review and meta—analysis[J]. Prostaglandins Other Lipid Mediat， 2025， 178： 106991.

[59] Wang Y, Jiang L, Feng SJ, et al. Effect of combined statin and antihypertensive therapy in patients with hypertension: a systematic review and meta—analysis[J]. Cardiology， 2020， 145(12): 802-812.

[60] Rosoff DB, Mavromatis LA, Bell AS, et al. Multivariate genome—wide analysis of aging—related traits identifies novel loci and new drug targets for healthy aging[J]. Nat Aging， 2023， 3(8): 1020-1035.

[61] Jensen NS, Wehland M, Wise PM, et al. Latest knowledge on the role of vitamin D in hypertension[J]. Int J Mol Sci, 2023, 24(5): 4679.

[62] Chen S, Gemelga G, Yeghiazarians Y . Is vitamin D supplementation an effective treatment for hypertension?[J]. Curr Hypertens Rep， 2022， 24(10): 445-453.

[63] Bollen SE, Bass JJ, Fujita S, et al. The vitamin D/vitamin D receptor (VDR) axis in muscle atrophy and sarcopenia[J]. Cell Signal， 2022， 96： 110355.

[64] Dwimartutie N, Setiati S, Tamin TZ, et al. Vitamin D levels in pre—frail older adults and its correlation with hand grip strength[J]. Acta Med Indones， 2023， 55(2): 172-179.

[65] Ni Lochlainn M, Cox NJ, Wilson T, et al. Nutrition and frailty: opportunities for prevention and treatment[J]. Nutrients, 2021, 13(7): 2349.

[66] Bislev LS, Grove—Laugesen D, Rejnmark L . Vitamin D and muscle health: a systematic review and meta—analysis of randomized placebo—controlled trials[J]. J Bone Miner Res， 2021， 36(9): 1651-1660.

[67] Dent E, Morley JE, Cruz—Jentoft AJ, et al. Physical frailty: ICFSR international clinical practice guidelines for identification and management[J]. J Nutr Health Aging， 2019， 23(9): 771-787.

[68] Barnish M, Sheikh M, Scholey A . Nutrient therapy for the improvement of fatigue symptoms[J]. Nutrients, 2023, 15(9): 2154.

[69] Ketchem JM, Bowman EJ, Isales CM . Male sex hormones, aging, and inflammation[J]. Biogerontology， 2023， 24（ 1）： 1-25.

[70] 李青泉, 和丽丽, 李刚 . 药物相关性高血压：经常发生却易被忽视的继发性高血压[J]. 中华高血压杂志， 2019， 27(7): 687-691.

[71] Bergen AW, Cil G, Sargent LJ, et al. Frailty risks of prescription analgesics and sedatives across frailty models: the health and retirement study[J]. Drugs Aging， 2022， 39(5): 377-387.

[72] Huang BB, Liu Q, Yu X, et al. Integrated analyses to identify the roles of GPX1 in frailty and hypertension[J]. Hypertension， 2025， 82(8): 1379-1391.

[73] Ramonfaur D, Buckley LF, Arthur V, et al. High throughput plasma proteomics and risk of heart failure and frailty in late life[J]. JAMA Cardiol， 2024， 9(7): 649-658.

[74] 中华中医药学会心血管病分会 . 高血压中医诊疗专家共识[J]. 中国实验方剂学杂志， 2019， 25(15): 217-221.

[75] 徐建凤 . 十味温胆汤加减治疗痰浊中阻型老年高血压合并衰弱的临床观察[D]. 昆明: 云南中医药大学, 2023.

[76] 李娟 . 加减益气活血汤治疗气虚血瘀型老年高血压并衰弱的临床观察[D]. 昆明: 云南中医药大学, 2022.

[77] 冯静, 黄沂, 彭霞, 等 . 中药穴位贴敷联合耳穴压豆对阴虚阳亢型老年高血压合并衰弱的临床观察[J]. 护理实践与研究， 2024， 21(5): 634-639.